CSL 346

Drug Profile

CSL 346

Alternative Names: 2H10; CSL-346

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Zenyth Therapeutics
  • Developer CSL; Zenyth Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Type 2 diabetes mellitus
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 10 Feb 2017 Preclinical trials in Diabetic nephropathies in Australia (SC) before February 2017 (9211410; CSL pipeline)
  • 10 Feb 2017 Preclinical data in mouse models released by CSL
  • 01 Dec 2016 CSL 346 is still in preclinical development for Type-2-diabetes-mellitus in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top